União Europeia -
letão -
EMA (European Medicines Agency)
azacitidine mylan
mylan ireland limited - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiski līdzekļi - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.
União Europeia -
letão -
EMA (European Medicines Agency)
zolgensma
novartis europharm limited - onasemnogene abeparvovec - muskuļu atrofija, mugurkaula - other drugs for disorders of the musculo-skeletal system - zolgensma ir indicēts, lai ārstētu:pacientiem ar 5q muguras muskuļu atrofija (sma) ar bi-allelic mutācija smn1 gēnu un klīniskā diagnoze sma tips 1, orpatients ar 5q sma ar bi-allelic mutācija smn1 gēnu un līdz 3 kopijas smn2 gēnu.
União Europeia -
letão -
EMA (European Medicines Agency)
ebvallo
pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.
